Antonello PETRELLA | Curriculum
Antonello PETRELLA Curriculum
Education and Professional Experience
2021 – Present: Full Professor of Pharmacology (SSD BIOS 11/A) DIFARMA, University of Salerno.
2014 – 2021: Associate Professor of Pharmacology (SSD BIO/14) DIFARMA, University of Salerno.
2005 – 2014: Researcher in Pharmacology (SSD BIO/14) DIFARMA, University of Salerno.
2006: Visiting Scientists, Department of Cellular & Molecular Neuroscience, Imperial College London.
2005: Visiting Scientists, William Harvey Research Institute, Queen Mary University of London.
2003 – 2004: Postdoctoral Fellow, Department of Pharmaceutical Sciences, University of Salerno.
1994 – 1998: PhD in Oncology, Faculty of Medicine and Surgery, Magna Græcia University of Catanzaro.
1991 – 1994: Specialization in Biochemistry and Clinical Chemistry, Faculty of Medicine and Surgery, University of Naples Federico II.
1989: Master of Science degree in Biological Sciences, Faculty of Mathematics, Physics and Natural Sciences, University of Naples Federico II.
Teaching Activities
Pharmacology and Pharmacotherapy, Toxicology and Chemotherapy
Institutional and Organizational Roles
2024 – Present: Head of Quality Assurance, Department of Pharmacy.
2022 – Present: Deputy Director, DIFARMA, University of Salerno.
2019 – 2022: President of single-cycle Degree Course in Pharmaceutical Chemistry and Technology
2018 – 2019: Member of the Academic Senate, University of Salerno.
2014 – 2020: Rector's Delegate as a member of the University of Salerno Quality Assurance Unit.
22011 – 2018: Coordinator of the Biomedical Section, Department of Pharmacy, University of Salerno
Research Projects and Responsibilities
Principal Investigator for various research projects funded by public and private institutions.
2023-2024: Principal Investigator, "Review and approval of technical documentation related to absorption, distribution, metabolism, and excretion (ADME) of medical devices," IBSA Farmaceutici Italia SRL.
2022-2023: Principal Investigator, "Review and approval of technical documentation related to absorption, distribution, metabolism, and excretion (ADME) of medical devices," IBSA Farmaceutici Italia SRL.
2021-2022: Principal Investigator, "Implementation of Patent Valorization Programs through Proof of Concept (PoC) Projects," funded by the Ministry of Economic Development. Patent No. 102018000010968 - COMPOSITION FOR THE TREATMENT OF SKIN LESIONS, UNISA.
2021-2022: Principal Investigator, "Evaluation of the efficacy of antimicrobial substances for skin and mucosal tissue repair," research contract between NEILOS Srl and DIFARMA.
2020: Principal Investigator, scientific collaboration agreement with Shedir Pharma s.r.l. on the "Evaluation of the activity of nutraceuticals in tissue repair."
2014-2020: Principal Investigator DIFARMA in the project "Ridiamo nuova vitA a riSorse preCedentemente non riciclabili Mediante una nuova Tecnologia processO-RINASCIMENTO" (PON 2014-2020).
2017, 2016: Principal Investigator, "Evaluation of the in vitro efficacy of Mesoglycan contained in PRISMASKIN for the treatment of skin lesions," Mediolanum Farmaceutici S.p.a.
2005-2024: Research funding from FARB.
Research Activities and Interests
The research focuses on molecular mechanisms involved in neoplastic progression and cellular regeneration as targets for the development of new pharmacological treatments.
Specific research areas include:
Study of CAF-1 in head and neck cancer progression.
Effects of Metformin in head and neck cancer.
Study of Annexin A1 in pancreatic cancer tumor progression.
Study of glycosaminoglycans/Mesolytican in tissue repair.
Characterization of natural or synthetic substances in cancer treatment
Recent Scientific collaborations
Since 2021, we have been collaborating with Professors Andrea Spallarossa and Chiara Brullo from the University of Genoa to study the in vitro effects of Pyrazole compounds in cancer treatment.
Since 2019, we have been collaborating with Dr. James Whiteford, Senior Lecturer at the William Harvey Research Institute, center of Microvascular Research, to study the role of Mesoglycan in fibrinolysis and pathophysiological angiogenesis.
Since 2018, we have been collaborating with Professor Iolanda De Marco from the Department of Industrial Engineering at the University of Salerno, studying the role of Mesolytican, a fibrinolytic drug, in tissue repair.
Since 2017, we have been collaborating with Professor Mauro Perretti from the "William Harvey Research Institute Barts and The London School of Medicine and Dentistry" (United Kingdom), to study the role of Annexin A1 in the pathophysiological processes of cellular migration/invasion and the effects of extracellular vesicles.
Technology Transfer Activities
Patents
BISOGNI R, LAMBERTI A, PETRELLA A, ROMANO MF, TURCO M.C., VENUTA S (2001). Nucleotide sequences and protein(s) encoded by such nucleotides for modulation of apoptosis. 2002235827 (AU); 527445 (NZ); 7589185 (US)
BISOGNI R, LAMBERTI A, PETRELLA A, ROMANO MF, TURCO M.C., VENUTA S (2001). Sequenza nucleotidica e corrispondente proteina in grado di regolare l'apoptosi.. 0001322989, UNIVERSITÀ DEGLI STUDI MAGNA GRAECIA DI CATANZARO
Patent No. 102018000010968 - COMPOSITION FOR THE TREATMENT OF SKIN LESIONS - UNIVERSITY OF SALERNO. Granted on October 30, 2020.
PCT/IB2019/060595: PCT patent extension filed on December 10, 2019.
